BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37857018)

  • 1. CDKN2A was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model.
    Wan H; Yang X; Sang G; Ruan Z; Ling Z; Zhang M; Liu C; Hu X; Guo T; He J; Liu D; Pei J
    Aging (Albany NY); 2023 Oct; 15(20):11244-11267. PubMed ID: 37857018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors.
    Zhang D; Wang T; Zhou Y; Zhang X
    Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
    Song S; Zhang M; Xie P; Wang S; Wang Y
    Front Immunol; 2022; 13():978909. PubMed ID: 36341328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
    Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
    BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artificial intelligence reveals dysregulation of osteosarcoma and cuproptosis-related biomarkers, PDHA1, CDKN2A and neutrophils.
    Jiang J; Zhan X; Wei J; Fan Q; Li H; Li H; Li S; Zhao Y; Yin G; Tang L; Wu Y; Lan M; Qin Y; Guo Q; Xu W; Lu L; Yang Y; Zhang Y; Qu H
    Sci Rep; 2023 Mar; 13(1):4927. PubMed ID: 36967449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
    Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X
    Front Oncol; 2023; 13():1152681. PubMed ID: 37333810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TJP3 promotes T cell immunity escape and chemoresistance in breast cancer: a comprehensive analysis of anoikis-based prognosis prediction and drug sensitivity stratification.
    Chaojun L; Pengping L; Yanjun L; Fangyuan Z; Yaning H; Yingbo S; Qi C; Hui L
    Aging (Albany NY); 2023 Nov; 15(22):12890-12906. PubMed ID: 37950731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas.
    Bao JH; Lu WC; Duan H; Ye YQ; Li JB; Liao WT; Li YC; Sun YP
    Front Immunol; 2022; 13():933973. PubMed ID: 36045691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of risk and clinical outcome of cuproptosis in lung squamous carcinoma.
    Zhang Y; Zhou J; Li H; Liu Y; Li J
    BMC Pulm Med; 2023 Jun; 23(1):205. PubMed ID: 37308925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in head and neck squamous cell carcinoma cancer.
    Jiang X; Ke J; Jia L; An X; Ma H; Li Z; Yuan W
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):203-218. PubMed ID: 36376617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nomogram based on cuproptosis-related genes predicts 7-year relapse-free survival in patients with estrogen receptor-positive early breast cancer.
    Fan Y; Luo C; Wang Y; Wang Z; Wang C; Zhong X; Hu K; Wang Y; Lu D; Zheng H
    Front Oncol; 2023; 13():1111480. PubMed ID: 37251943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma.
    Wang L; Yao B; Yang J; Tian Z; He J
    BMC Cancer; 2022 Nov; 22(1):1131. PubMed ID: 36333684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of a novel cuproptosis-related signature as a prognostic model for lung adenocarcinoma.
    Chen Y; Tang L; Huang W; Zhang Y; Abisola FH; Li L
    Front Endocrinol (Lausanne); 2022; 13():963220. PubMed ID: 36353226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis-related gene CDKN2A as a molecular target for IPF diagnosis and therapeutics.
    Xu B; Yang K; Han X; Hou J
    Inflamm Res; 2023 Jun; 72(6):1147-1160. PubMed ID: 37166466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of cuproptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer.
    Li Z; Zhang H; Wang X; Wang Q; Xue J; Shi Y; Wang M; Wang G; Zhang J
    Front Immunol; 2022; 13():996836. PubMed ID: 36059516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y; Zhang Q; Zhang H; Kong F
    Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
    Jiang H; Chen H; Wang Y; Qian Y
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma.
    Li J; Yin J; Li W; Wang H; Ni B
    Cancer Cell Int; 2023 Jan; 23(1):7. PubMed ID: 36647100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.